Preparation after more than 3 months，China Pharmaceutical (600056)、Tianfang Pharmaceutical (600253) announced the official asset reorganization plan on August 15，GM Medical asset reorganization final finalization，China Pharmaceutical Stock Exchange Absorption Merge Fang Fang Pharmaceutical and Receive Assets will be done。
Two companies also announced the mid -term performance report on the 15th at the same time，China Medicine achieved operating income from January to June of 4.441 billion yuan，increased by 35.61%year -on -year，Net profit attributable to shareholders of listed companies is 202 million yuan，increased by 58.44%year My stake betting app-on stake sports betting app-year，Deducting net profit of 193 million yuan after deducting non -recurring gains and losses，increased by 70.49%year -on -year。Compared with the total net profit of 15.901 million yuan achieved by Tianfang Pharmaceutical from January to June, the total amount of net profit and 43.47%of the performance decline，Chinese medicine & ldquo; Marrying & rdquo; Tianfang Pharmaceutical is full of confidence。
Pharmaceutical assets of General Medicine
Reorganization report display，Chinese Medicine after the absorption of the stock exchange and merging Tianfang Pharmaceutical，It will issue shares to the controlling shareholder Universal Technology Group to purchase unlisted pharmaceutical assets，Including 35%equity of Hainan General Sanyo Pharmaceutical Co., Ltd.、Beijing Xinxing Huayang Pharmaceutical Co., Ltd. 100%equity、Wuhan Xinyi Investment Co., Ltd. 51%equity and Xinjiang Tianfang Hengde Pharmaceutical Co., Ltd. 51%equity。Subsequently, New China Medicine will select the opportunity to distribute shares to specific investors to support financing。Compared with the reorganization plan，The stock price of issuing shares and supporting financing is adjusted to 20.64 yuan/share。
The official asset reorganization plan is clear，The provider of the cash selection rights and the right to acquire the right to acquisition of the acquisition request is provided by General Technology Group;，Corresponding to 2011, the net profit attributable to the parent company is about 34 million yuan，P / E ratio is about My stake betting app8.stake betting app92 times; the upper limit of the amount of reorganized supporting financing will reach 996 million yuan，All used to supplement subsequent mobile funds。
The person in charge of Chinese medicine said，General Technology Group is confident in the reorganization，And long -term optimistic about the development prospects after the merger，It is planned to inject asset -earnings ratio of only 8.92 times，Inject consideration is lower than the average level of comparable listed companies。The issuance price of supporting financing is consistent with the capital injection issuance price，No more 10 % off，Show the affirmation of the major shareholders and management of the company's future development expectations。
The pharmaceutical industry and business are equal to
Chinese Medicine, which has a rapid growth of profitability, has served as a reorganization of general pharmaceutical assets。The mid -term performance report announced on the 15th of China Medicine，Significant growth of the company's overseas business helps to grow profitable。After deducting non -recurring gains and losses，The company's medium -term net profit reaches 193 million yuan，increased by 70.49%year -on -year。and Tianfang Pharmaceutical is much inferior，The net profit attributable to shareholders of listed companies in the first half of the year decreased by 43.47%year -on -year。
Chinese Medicine Representation，Before the reorganization, Chinese medicine focuses My stake betting appon stake online sports bettingcommercial circulation and international trade，Tianfang Pharmaceutical focuses on pharmaceutical research and development and production，New China Medicine after reorganization will achieve complementary advantages and integration of complete industrial chain，In particular, the scale of international trade business is expected to be further expanded。
After the reorganization is completed，New China Pharmaceutical will have more than 700 products and specifications in the pharmaceutical industry，Products cover the raw medicine、Chemical preparations、Chinese patent medicine, etc.，Main covering antibiotics、Anti -virus、Cardiovascular and cerebrovascular treatment fields。Medical Business aspect，New China Pharmaceutical Business Network will expand significantly，Have covered Beijing、Guangzhou、Henan、Hebei、Hubei、Xinjiang and other key provinces and cities in the medical business direct sales network，and the medical business allocation network covering 28 provinces, autonomous regions and municipalities，New Company will further coordinate the upstream and downstream resources of pharmaceutical business，Improve the right to speak。International Trade，Chinese medicine currently covers almost almost various countries and regions around the world，The company will be based on the original mature international trade network，Further excavate product export potential。
My stake betting appThe stake betting appdata provided by the company，After the reorganization is completed，It is expected that New China Medicine is expected to achieve a net profit of 350 million yuan in 2012，It is expected to achieve a net profit of 430 million yuan in 2013。
